The potential effects of a carbonic anhydrase IX (CAIX) inhibitor, SLC-0149, on AD pathogenesis

Alzheimers disease (AD) is the most common neurodegenerative disorder. SignalChem LifeSciences Corp. recently developed a potent small molecule inhibitor (SLC-0149) for targeting CAIX, a hypoxia inducible gene, in the application of treating cancers. Since hypoxia has been implicated as a factor to facilitate AD development, this study aims to explore the potentiality of applying SLC-0149 to treat AD model mice. More specifically, we will focus on the effects of SLC-0149 on two neuropathological features in AD, including A? deposition and Tau phosphorylation. The partner organization will gain novel knowledge of this drug in treating AD, and possibly extend the applicable scope of this compound.

Faculty Supervisor:

Weihong Song

Student:

Yufei Wu

Partner:

SignalChem Lifesciences Corporation

Discipline:

Psychology

Sector:

Medical devices

University:

Program: